n response to an ongoing, unprecedented outbreak of Ebola virus disease (EVD) in West Africa, a team of researchers from the Broad Institute and Harvard University, in collaboration with the Sierra Leone Ministry of Health and Sanitation and researchers across institutions and continents, has rapidly sequenced and analyzed more than 99 Ebola virus genomes. Their findings could have important implications for rapid field diagnostic tests. The team reports its results online in the journal Science.
For the current study, researchers sequenced 99 Ebola virus genomes collected from 78 patients diagnosed with Ebola in Sierra Leone during the first 24 days of the outbreak (a portion of the patients contributed samples more than once, allowing researchers a clearer view into how the virus can change in a single individual over the course of infection). The team found more than 300 genetic changes that make the 2014 Ebola virus genomes distinct from the viral genomes tied to previous Ebola outbreaks. They also found sequence variations indicating that, from the samples sequenced, the EVD outbreak started from a single introduction into humans, subsequently spreading from person to person over many months.
The variations they identified were frequently in regions of the genome encoding proteins. Some of the genetic variation detected in these studies may affect the primers (starting points for DNA synthesis) used in PCR-based diagnostic tests, emphasizing the importance of genomic surveillance and the need for vigilance. To accelerate response efforts, the research team released the full-length sequences on National Center for Biotechnology Information's (NCBI's) DNA sequence database in advance of publication, making these data available to the global scientific community.
"By making the data immediately available to the community, we hope to accelerate response efforts," said co-senior author Pardis Sabeti, a senior associate member at the Broad Institute and an associate
Big tax monies from the stock market /all a big game for tax dollars .more than likely over a trillion in market taxes and then you will see all the good news for the start of it all over again.
(Update: The CDC confirmed Tuesday its first Ebola case in the United States.)
The Ebola outbreak could skyrocket to between 550,000 cases and 1.4 million cases by 2015 if there is no large-scale intervention, according to the Centers for Disease Control and Prevention. The CDC warns the epidemic in West Africa could drag on for years if a response isn’t immediate. Here are the latest figures on the largest Ebola outbreak in modern history.
1.4 million: The estimated number of Ebola cases in Liberia and Sierra Leone by the end of January if virus continues to spread.
will cost short sellers much later..just a era
Part of story
A third candidate is called AVI-7537, being developed by Sarepta Therapeutics in Cambridge, Mass. Sarepta started to develop this drug in 2010 under a contract with the U.S. military to work on drugs for Ebola and the closely related Marburg virus.
"The Ebola study got discontinued in late 2012 because of the fiscal budgetary issues in the United States at the time," says Dr. Michael Wong, senior medical director for infectious diseases at Sarepta.
Early tests showed the drug appeared safe in a small sample of people and fairly effective in treating monkeys with Ebola. But the budget cut stopped further tests.
Wong says there's enough of this potential drug for 25 patients to receive a full course of treatment, which should be sufficient for initial tests in West Africa. If those results are promising, the company has enough ingredients to make another 100 to 150 doses. But that's still a minuscule supply.
Sarepta would like to produce tens of thousands of doses in a matter of months. "That's the corporate goal," Wong says
It has been well known by us longs for years that these drugs here will stop the replication of many single strand viruses